UK research hub launched to tackle rare kidney disease
The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.
Archives for January 31, 2022
Biogen promises increased diversity in Phase 4 Aduhelm trial
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimer’s drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
Altimmune obesity drug candidate lands IND clearance from the FDA
The pharma firm has announced the agency has approved the company’s investigational new drug application for its Phase II trial of pemvidutide for obesity.